Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by Transperanceon Jan 01, 2023 8:01am
196 Views
Post# 35198871

RE:AGM

RE:AGMLake O,

Thanks for sharing with us, I am happy you attended. Would have joined you if I was around, but since I live in Northern Europe, this is not really an option.

Regular QA-sessions would be a good thing, but if the company was more transparent as to deal details and also as to what is going on in the company, that would certainly be preferred.
It would be good to understand the strategy going forward, what actions have been implemented and what actions are planned for, including a timetable.

The company communicated a number of statements in the June 15 News Release, and it would be a good thing if they also followed through on these statements. Alternatively, the trustworthiness of management will be weakened further.

Items to be answered could, for instance, be:

1 What steps for sustainable and rapid growth of the company have been initiated? And what steps are planned, including timetable.

2 What is the status of the strategic review of every facet of the company that the Board has begun? When is the review to be finalized and the conclusion communicated?

3 What is the status of organizational changes and management expansion?

4 Updates have not been communicated throughout the remainder of 2022 as stated. Will there be a change in communication policy in order to comply with company public statements?

5 What is the status of ramp-up and acceleration of pipeline development?

6 Sirona has stated that they will seek institutional analysis and investment. How is this going to be executed? It is not possible without a transparent approach where these parties are given figures. If institutional investors are given figures but not retail investors, this must be reported to the authorities. All stakeholders must be given the same amount of information at the same time.

7 Is Wolfgang still around? What has he been up to since arriving and what is the plan for him going forward?

The consequence of the present non-disclosure policy is that today only management knows if the deal with Abbvie was a successful one and only management knows if Sirona is a good buy or a good sell at the current stock price. The consequence of being non-transparent is also that the stock price deteriorates since it is impossible for new investors to do a due diligence of the company. This is since no numbers are provided. New investors, including professional institutional investors, will see this instantly.

Wish all long-time investors a happy new 2023. Last year was a terrible one in Northern Europe.

<< Previous
Bullboard Posts
Next >>